FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma
Figure 12.The correlation of drug sensitivity and cancer pathway activity about FARSB in HCC patients. (A) FARSB-related cancer pathway activity. (B) FARSB-related drug sensitivity using GDSC.